Canaccord Genuity Analysts Give Aptose Biosciences, Inc. (APTO) a $7.00 Price Target
Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) has been given a $7.00 price target by equities researchers at Canaccord Genuity in a report released on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s target price would indicate a potential upside of 295.48% from the company’s previous close.
A number of other brokerages have also recently weighed in on APTO. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Monday, August 14th. HC Wainwright raised Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $1.00 to $4.00 in a research report on Thursday, September 7th. Roth Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research report on Monday, October 23rd. Finally, ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $5.90.
Shares of Aptose Biosciences (NASDAQ APTO) traded down $0.13 during trading hours on Wednesday, hitting $1.77. The company’s stock had a trading volume of 311,656 shares, compared to its average volume of 397,298. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $2.20.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/16/canaccord-genuity-analysts-give-aptose-biosciences-inc-apto-a-7-00-price-target.html.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.